These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 8677971)

  • 21. [Depressive disorders and interferon alpha].
    Hardy P
    Gastroenterol Clin Biol; 1996; 20(3):255-7. PubMed ID: 8763063
    [No Abstract]   [Full Text] [Related]  

  • 22. Axonal neuropathy in a patient receiving interferon-alpha therapy for chronic hepatitis C.
    Tambini R; Quattrini A; Fracassetti O; Nemni R
    J Rheumatol; 1997 Aug; 24(8):1656-7. PubMed ID: 9263170
    [No Abstract]   [Full Text] [Related]  

  • 23. Management of chronic hepatitis B and C.
    Dusheiko GM
    S Afr Med J; 1994 Aug; 84(8 Pt 2):563-70. PubMed ID: 7863401
    [No Abstract]   [Full Text] [Related]  

  • 24. Mechanisms of thrombocytopenia induced by interferon therapy for chronic hepatitis B.
    Sata M; Yano Y; Yoshiyama Y; Ide T; Kumashiro R; Suzuki H; Tanikawa K
    J Gastroenterol; 1997 Apr; 32(2):206-10. PubMed ID: 9085169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Factors of response to treatment with interferon-alpha in patients with chronic hepatitis C. Therapeutic perspectives].
    Marcellin P; Pouteau M; Martinot M; Boyer N; Castelnau C; Benhamou JP; Erlinger S
    Gastroenterol Clin Biol; 1995 Dec; 19(12):991-1000. PubMed ID: 8729410
    [No Abstract]   [Full Text] [Related]  

  • 26. Chronic viral hepatitis and use of interferon. Whom are we treating?
    Koretz RL
    Postgrad Med; 1996 Sep; 100(3):55-7, 61-2, 68. PubMed ID: 8795646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of granulomatous hepatitis during treatment with interferon-alpha 2b.
    Propst A; Propst T; Dietze O; Kathrein H; Judmeier G; Vogel W
    Dig Dis Sci; 1995 Oct; 40(10):2117-8. PubMed ID: 7587776
    [No Abstract]   [Full Text] [Related]  

  • 28. [Anti-platelet antibody and severe thrombocytopenia during interferon-alpha therapy for chronic active hepatitis C].
    Tanaka Y; Hayashida K; Ikematsu W; Umeno M; Ishibashi H; Niho Y
    Nihon Rinsho Meneki Gakkai Kaishi; 1996 Apr; 19(2):150-6. PubMed ID: 8705692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapy of chronic hepatitis B, C and D with alpha-interferon].
    Niederau C
    Fortschr Med; 1993 Feb; 111(6):35-7. PubMed ID: 8462911
    [No Abstract]   [Full Text] [Related]  

  • 30. Antithyroid peroxidase antibody and development of silent thyroiditis during interferon-alpha 2a treatment of chronic hepatitis C.
    Wada M; Shimoyama T; Hamada A; Fukuchi M
    Am J Gastroenterol; 1995 Aug; 90(8):1366-7. PubMed ID: 7639264
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical use of interferons in hepatology.
    Civeira MP
    Methods Find Exp Clin Pharmacol; 1996; 18 Suppl B():33-4. PubMed ID: 8899691
    [No Abstract]   [Full Text] [Related]  

  • 32. Interferon therapy for chronic hepatitis C.
    Davis GL
    Baillieres Clin Gastroenterol; 1996 Jul; 10(2):289-98. PubMed ID: 8864035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained response to interferon in a patient with common variable immunodeficiency and hepatitis C.
    Castro F; Santaella M; Torres EA; Rodriguez-Medina JR; González-Keelan C
    Am J Gastroenterol; 1997 Sep; 92(9):1557-8. PubMed ID: 9317087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [How should hepatitis C be monitored? Monitoring of treated hepatitis C].
    Larrey D
    Gastroenterol Clin Biol; 1997; 21(1 Pt 2):S99-110. PubMed ID: 9161521
    [No Abstract]   [Full Text] [Related]  

  • 35. Interferon therapy in hepatitis C--refractory hepatitis--report of the research subgroup of treatment of chronic hepatitis.
    Iino S
    Gastroenterol Jpn; 1993 Mar; 28 Suppl 4():139-42. PubMed ID: 8486225
    [No Abstract]   [Full Text] [Related]  

  • 36. [Mucocutaneous lichen planus induced by a second treatment with high-dose interferon-alpha in a patient with chronic viral hepatitis C].
    Perreard M; Constant T; Monges D; Djaghri N; Angeli-Besson C; Gerolami A
    Gastroenterol Clin Biol; 1994; 18(11):1051. PubMed ID: 7705576
    [No Abstract]   [Full Text] [Related]  

  • 37. [Therapy of viral hepatitis].
    Rambusch EG; Manns MP
    Ther Umsch; 1998 Feb; 55(2):71-6, 78-9. PubMed ID: 9545847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune thrombocytopenia after alpha-interferon therapy in a patient with chronic hepatitis C.
    López Morante AJ; Sáez-Royuela F; Casanova Valero F; Yuguero del Moral L; Martín Lorente JL; Ojeda Giménez C
    Am J Gastroenterol; 1992 Jun; 87(6):809-10. PubMed ID: 1590332
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN.
    Milella M; Antonelli G; Santantonio T; Giannelli G; Currenti M; Monno L; Turriziani O; Pastore G; Dianzani F
    Hepatogastroenterology; 1995 Jul; 42(3):201-4. PubMed ID: 7590565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sarcoidosis after interferon therapy for chronic active hepatitis C.
    Teragawa H; Hondo T; Takahashi K; Watanabe H; Ohe H; Hattori N; Watanabe Y; Amano H; Hino F; Ohbayashi M; Urushihara T; Yonehara S
    Intern Med; 1996 Jan; 35(1):19-23. PubMed ID: 8652926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.